Gottlieb's Complex Generics Remarks Could Signal (Some) Increased Flexibility
US FDA commissioner spoke to agency scientists and researchers at Generic Drug Science Day, where he discussed future plans to facilitate complex generic development.
You may also be interested in...
By conducting a product development or pre-submission meeting, sponsors can receive a mid-review cycle meeting for a complex product ANDA.
New FDA Commissioner tells employees that 'too many consumers are priced out of medicines they need' and that FDA must take meaningful steps to get lower cost alternatives to market.
US agency could reconsider requirement that instructions for use be same for branded and generic products, FDA Commissioner-nominee Scott Gottlieb suggests, while also leaving door open to statutory changes in Hatch-Waxman Act.